Table 6. Disease modifying therapy use in care units.
| ß-IFN | DMF | GA | TFL | FG | CLA | NAT | ALM | OCR | |
|---|---|---|---|---|---|---|---|---|---|
| 1. | X | X | X | X | X | X | X | X | X |
| 2. | X | X | X | X | X | X | X | X | |
| 3. | X | X | X | X | X | X | X | X | X |
| 4. | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| 5. | X | X | X | X | X | X | X | X | X |
| 6. | X | X | X | X | X | X | X | X | X |
| 7. | X | X | X | X | X | X | X | X | |
| 8. | X | X | X | X | X | X | |||
| 9. | X | X | X | X | X | X | X | X | X |
| 10. | X | X | X | X | X | X | X | X | |
| 11. | X | X | X | X | X | X | X | X | X |
| 12. | X | X | X | X | X | X | X | X | |
| 13. | X | X | X | X | X | X | X | X | X |
| 14. | X | X | X | X | X | ||||
| 15. | X | X | X | X | X | X | X | X | X |
| 16. | X | X | X | X | X | X | X | X | X |
| 17. | X | X | X | X | X | X | X | X | X |
| 18. | X | X | X | X | X | ||||
| 19. | X | X | X | X | X | X | X | X | X |
| 20. | X | X | X | X | X | X | X | X | X |
| 21. | X | X | X | X | X | ||||
| 22. | X | X | X | X | X | X | X | X | X |
| 23. | X | X | X | X | X | X | X | ||
| 24. | X | X | X | X | X | X | |||
| 25. | X | X | X | X | X | X | X | ||
| 26. | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| 27. | X | X | X | X | X | X | X | X | X |
| 28. | X | X | X | X | X | X | X | X | X |
| 29. | X | X | X | X | X | X | X | X |
In the first column respondent Hungarian Multiple sclerosis care units (numbered from 1 to 29) are listed, in the first row, abbreviations of disease modifying therapies’ active substances are listed.
“X” indicates that the disease modifying therapy is used in the care units, cell with a grey background indicates that the disease modifying therapy is not used in the care unit, “N/A” means that no data were supplied.
Abbreviations: ALM = alemtuzumab, ß-IFN = ß-interferon, CLA = cladribine, DMF = dimethyl fumarate, FG = fingolimod, GA = glatiramer acetate NAT = natalizumab, OCR = ocrelizumab, TFL = teriflunomide.